• Research & Development

  Morphogen-IX Gets $23.2M to Develop New PAH Therapy

  Posted by Pulmonary Hypertension News Moderator on January 9, 2019 at 2:03 pm

  Morphogen-IX has raised $23.2 million to advance development of MGX292, its lead drug candidate for treatment of pulmonary arterial hypertension. Click here to learn more.

  What do you think about this news?

  replied 5 years, 4 months ago 1 Member · 0 Replies
• 0 Replies

Log In to Reply